Agena Bioscience Eyes New Year Target For Mass Spec Liquid Biopsy Launch
Agena Bioscience will launch two diagnostic panels for targeted testing of lung and colon cancer in Europe in January. The liquid biopsy technology is based on its benchtop mass spectrometer, the MassArray Dx Analyzer 4.
You may also be interested in...
The use of mass spectrometry in IVD applications looks to be gaining momentum. In this article, Alina Kim, Sunayana Karra and Akash Kundu of Boston Biomedical Consultants report on new developments and innovations showcased at the American Association for Clinical Chemistry Annual (AACC) & Clinical Lab Expo (CLE) annual meeting that took place this summer. Players at the convention exhibited a range of Class I medical devices, research use only liquid chromatography tandem mass spectrometry (LC-MS/MS), matrix-assisted laser desorption/ionization (MALDI-TOF), inductively coupled plasma mass spectrometry (ICP-MS), sample preparation automation platforms, and software solutions.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.